CN101143203B - Compound oral liquid with liver-protecting and stomach-nourishing function - Google Patents
Compound oral liquid with liver-protecting and stomach-nourishing function Download PDFInfo
- Publication number
- CN101143203B CN101143203B CN2006100310126A CN200610031012A CN101143203B CN 101143203 B CN101143203 B CN 101143203B CN 2006100310126 A CN2006100310126 A CN 2006100310126A CN 200610031012 A CN200610031012 A CN 200610031012A CN 101143203 B CN101143203 B CN 101143203B
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- radix
- liver
- chinese medicine
- compound oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 68
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 20
- 210000001156 gastric mucosa Anatomy 0.000 claims abstract description 15
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 8
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000012153 distilled water Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 206010067125 Liver injury Diseases 0.000 claims description 9
- 230000002421 anti-septic effect Effects 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims description 7
- 239000004299 sodium benzoate Substances 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 235000021433 fructose syrup Nutrition 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- 241000143437 Aciculosporium take Species 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 235000019082 Osmanthus Nutrition 0.000 claims description 2
- 241000333181 Osmanthus Species 0.000 claims description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004283 Sodium sorbate Substances 0.000 claims description 2
- 102000011759 adducin Human genes 0.000 claims description 2
- 108010076723 adducin Proteins 0.000 claims description 2
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 claims description 2
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 229930003944 flavone Natural products 0.000 claims description 2
- 150000002213 flavones Chemical class 0.000 claims description 2
- 235000011949 flavones Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 claims description 2
- 235000019250 sodium sorbate Nutrition 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 19
- 208000024891 symptom Diseases 0.000 abstract description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 9
- 210000002784 stomach Anatomy 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 8
- 208000007882 Gastritis Diseases 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 7
- 230000001681 protective effect Effects 0.000 abstract description 6
- 208000023652 chronic gastritis Diseases 0.000 abstract description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 108010024636 Glutathione Proteins 0.000 abstract description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract 1
- 108010082126 Alanine transaminase Proteins 0.000 abstract 1
- 235000004032 Centella asiatica Nutrition 0.000 abstract 1
- 244000146462 Centella asiatica Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000010000 Hovenia dulcis Species 0.000 abstract 1
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 229940118019 malondialdehyde Drugs 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a compound oral liquid, which has the functions of protecting liver and nourishing stomach and the preparation method of the compound oral liquid. The oral liquid of the invention is made from the medicine-food homologous medicinal materials of a kudzuvine root, a Japanese raisin tree seed, a dry ginger, a dried tangerine peel, a rhodiola rosea, an Asiatic pennywort herb etc. by the modernized processing technology of the traditional Chinese medicine. The invention aims at providing a compound oral liquid, which is purely natural, safe and effective and is convenient for taking, so as to achieve the efficacies of protecting liver and nourishing stomach. The function test testifies that the oral liquid can obviously reduce the standards of serum glutamic-pyruvic transaminase, glutamic-oxaloacetic transaminase, triglyceride and malondialdehyde and increase the content of reduced glutathione to relieve the pathological symptoms of the hepatic injury; the oral liquid has protective effect towards the chemical hepatic injury and the alcoholic hepatic injury. Thirty three cases of the patients with chronic gastritis take the oral liquid for one month, and the clinical symptom and the physical sigh of the patients are improved, which indicates that the oral liquid has the effect of protecting the gastric mucosa.
Description
Technical field:
The present invention relates to a kind ofly has the compound oral liquid of protective effect to chemical liver injury and gastric mucosa injury, relates in particular to its prescription, preparation technology and health-care effect.
Background technology:
Along with the change of raising, life style and the dietary structure of people's living standard, hobby the alcohol user also increase year by year in recent years.Often drinking to cause hepatic injury and gastric mucosa injury, and severe patient can cause alcoholic fatty liver, alcoholic hepatitis, hepatic fibrosis and gastric ulcer, thereby is detrimental to health, influences quality of life.
The Western medicine that is used for the treatment of hepatopathy and gastropathy at present, its toxic and side effects need rely on liver and eliminate, and this is impairing the liver again in treating the liver beyond doubt, becomes another inducement of chemical liver injury; Chinese medicine is compared with the obvious advantage with Western medicine, but the dosage of its part component is unsuitable for taking for a long time, is difficult to satisfy the healthy health care needs of people; And most of health food is only started with from the angle that protects the liver, and still reckons without protection gastric mucosa in the liver benefiting, thereby reaches the double effects of promoting digestion, protecting liver in the process of drinking for a long time; The liver protecting health food is mostly based on tablet, capsule in addition, take in the body of back absorb, speed of action is slower, can not reach the purpose of removing malaise symptoms behind the insobriety rapidly.
Therefore, starting with from hepatoprotective, nourishing the stomach double health effect, take into account safety, develop that toxic and side effects is low, exact efficacy, the oral formulations that is suitable for taking for a long time, and select to be easy to the dosage form of absorption of human body, is the current problem that solves of needing.
Summary of the invention
For overcoming the defective of above-mentioned prior art, the object of the present invention is to provide a kind of have liver-protecting and stomach-nourishing double effects, safe and reliable, the compound oral liquid that is suitable for taking for a long time and being easy to absorption of human body.
The key of realization above-mentioned purpose is the prescription and the preparation method of oral liquid of the present invention:
Oral liquid of the present invention utilizes prescription advantage, the good medicinal and edible Chinese medicine material of selection safety of motherland's tradition Chinese medicine, uses modernized Chinese medicine processing technique to be prepared from.Use following weight raw material among every 1000ml, the adding pharmaceutical adjunct is processed into after processes such as extraction, precipitate with ethanol:
Pericarpium Citri Reticulatae 150-170g Radix Salviae Miltiorrhizae 100-120g
Semen Hoveniae (Fructus Hoveniae) 110-130g Radix Angelicae Sinensis 80-100g
Radix Puerariae 80-100g Radix Bupleuri 150-170g
Radix Rhodiolae 110-130g Herba Centellae 100-150g
Rhizoma Zingiberis 100-120g
Also add following pharmaceutical adjunct: sweeting agent 50-100g, antiseptic 0.2-2g, aromatic 0.5-2g, citric acid 0.5-1.5g, distilled water surplus.
Described sweeting agent is one or more the mixture that is selected from sucrose, high fructose syrup, protein sugar, crude sweet echinacoside, the saccharin sodium etc.; Antiseptic is one or more the mixture that is selected from benzoic acid, sodium benzoate, sorbic acid, sodium sorbate, Metagin, second, the propyl ester etc.; Aromatic is to be selected from a kind of in Herba Menthae essence, coffee aroma, osmanthus flower fragrance, strawberry essence, the flavoring pineapple essence etc.
Antiseptic selects sodium benzoate comparatively suitable, the reasons are as follows: liquid preparation easily pollutes for Institute of Micro-biology, and one comes it to contain nutrient substance, suitable microbial growth and breeding; Two come it to contain the condition that moisture is antibacterial and fungus growth; Three to come pH value be that 4-6 is that mycete is the environmental field of suitable growth.Sodium benzoate is a kind of effective antiseptic, its dissolubility in water is 1: 1.8, antisepsis is identical with benzoic acid in acid solution, best fungistatic effect is arranged, and it all has good inhibitory effect to mycete, yeast and other assorted bacterium in sacchariferous solution.The pH value scope of oral liquid of the present invention is 4-6 and contains a certain amount of sweeting agent, so select for use sodium benzoate comparatively suitable as antiseptic according to its preparation characteristic.
Oral liquid preparation process of the present invention may further comprise the steps:
A. take by weighing Radix Puerariae, Semen Hoveniae (Fructus Hoveniae), Radix Rhodiolae, Pericarpium Citri Reticulatae, Rhizoma Zingiberis, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Radix Bupleuri and the Herba Centellae that is ground into coarse powder by proportioning, added water infiltration 2 hours, adding water to 10 times, 8 times amounts respectively decocts 2 times, each two hours, filter, merging filtrate is evaporated to 1/2 of medical material weight, forms the Chinese medicine concentrated solution;
B. in the Chinese medicine concentrated solution, add 95% alcoholic solution of 3 times of amounts (volume ratio), stir half an hour, precipitate with ethanol 24 hours; Filter, filtrate recycling ethanol is not to there being the alcohol flavor, and cooling back adding distil water standardize solution forms Chinese medicine extraction liquid to 1.5 times of the medical material total amount;
C. by proportioning, in Chinese medicine extraction liquid, add sweeting agent and citric acid, mix homogeneously;
D. be warming up to 90-100 ℃, heat sterilization is incubated half an hour, is cooled to 30 ℃, adds aromatic and antiseptic, and fully mixing is added distilled water to full dose;
E. behind plate-and-frame filtration, be filled into bottle.
Oral liquid of the present invention is that light coffee color, density are that 1.05-1.15g/ml, pH value are the liquid of 4-6.
Oral liquid of the present invention detects through functional component, contains total flavones 110-140mg, puerarin 15-20mg, rhodioside 25-30mg in every 100ml oral liquid.
Another technical problem to be solved by this invention is to disclose the application of above-mentioned compound oral liquid in protection chemical liver injury and gastric mucosa injury.
In the oral liquid prescription of the present invention, Radix Puerariae, Radix Bupleuri heat-clearing and toxic substances removing, Semen Hoveniae (Fructus Hoveniae) liver heat removing dampness removing is equipped with Pericarpium Citri Reticulatae, Rhizoma Zingiberis, Radix Rhodiolae regulating qi-flowing for strengthening spleen, and hepatic injury is had auxiliary protection function.Select Herba Centellae, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling in the while side for use, Radix Angelicae Sinensis and blood are moisturized, and are equipped with the Rhizoma Zingiberis stomach function regulating that helps digestion, and the Pericarpium Citri Reticulatae replenishing QI to invigorate the spleen reaches the effect of protection gastric mucosa.All medicine reasonable compatibilities are brought into play the double health effect of hepatoprotective, nourishing the stomach jointly.Function test proves that this oral liquid can obviously reduce serum glutamic pyruvic transminase and glutamic oxaloacetic transaminase, GOT content, triglyceride and mda content, and the sweet peptide content of rising reproducibility paddy flesh is alleviated the hepatic injury pathological symptom; Simultaneously 33 routine chronic gastritis patients take this oral liquid after one month clinical symptoms and sign make moderate progress.
Oral liquid of the present invention has carried out the animal health functional evaluation through Shanghai City preventive medicine academy according to " the health food function assessment assessment process and the method for inspection ", and method and result are as follows:
1, to the auxiliary protection function of chemical liver injury:
1.1 experimental technique: according to human body recommended dose 50ml/60kg, with laboratory animal Kunming kind white mice (18-22 gram) establish low (4.2ml/kg), in (8.3ml/kg), high (25ml/kg) three dosage groups, other establishes liver injury model group and normal control group.Each dosage group is given oral liquid, and matched group and model group are drunk distilled water, continuous 30 days.The 30th day each dosage group and model group CCL
4Contamination, dosage 24mg/kg, lumbar injection (i.p).The 31st day, 5 treated animals were plucked eyeball and got blood, and are centrifugal, get serum, measure biochemical indicator: serum glutamic pyruvic transminase (GPT), glutamic oxaloacetic transaminase, GOT (GOT), white/globulin ratio (A/G); And get liver and carry out histopathologic examination.Experimental result Spss software statistics.
1.2 experimental result
Biochemistry detection result
*P＜0.05 and CCL
4Model group is (through variance analysis) relatively
As seen from the above table, the GPT of normal control group, GOT content are starkly lower than CCL
4There is significant difference in model group, and the model establishment is described; GPT, the GOT of the middle and high dosage group of oral liquid all obviously reduces, with CCL
4Relatively all there is significant difference in model group.
The pathologic finding total mark
*P＜0.05 and CCL
4Model group is (through variance analysis) relatively
By check substantially and the microscopy result as seen, the pathology integration of normal control group is starkly lower than CCL
4There is significant difference in model group, and the model establishment is described.Middle and high dosage group of oral liquid and CCL
4Model is compared, and the pathology integration obviously descends, and has significant difference.
1.3 experiment conclusion: the animal per os gave oral liquid after 30 days, had the protective effect to hepatic injury due to the chemical substance.
2, to the protective effect of the clear liver damage of wine:
2.1 experimental technique: according to human body recommended dose 50ml/60kg, establish 2.25,4.5,8.5, four dosage groups of 25ml/kg, other establishes 50% ethanol liver injury model group and distilled water negative control group.Select 60 of healthy Kunming kind white mice (18-22 gram), be divided into 6 groups at random, 10 every group.Each dosage group gives oral liquid, and negative control group and model group are drunk distilled water, continuous 30 days.The 30th day each dosage group and model group give 50% ethanol 0.12ml/10g.bw contamination.After the fasting 12 hours, each treated animal is got liver, makes 10% liver homogenate, measures following biochemical indicator respectively: triglyceride (TG), malonaldehyde (MDA), reductive glutathione (GSH); And get liver and carry out histopathologic examination.Experimental result Spss software statistics.
2.2 experimental result:
Biochemistry detection result
*Compare with the ethanol model group p＜0.05, through variance analysis
As seen from the above table, the TG of normal control group, MDA, GSH compare with the ethanol model group, all have significant difference, and the model establishment is described; TG, the MDA of 25ml/kg dosage group, GSH compare with the ethanol model group, all have significant difference.2.3 experiment conclusion: the animal per os gave oral liquid after 30 days, and alcoholic liver injury is had protective effect.
3, protection gastric mucosa effect:
3.1 experimental technique: according to human body recommended dose 50ml/60kg, establish 2.25,4.5,8.5, four dosage groups of 25ml/kg, other establishes negative control group and positive controls.Get 60 of healthy adult SD rats (60-80 gram), be divided into 6 groups at random, 10 every group.Each dosage group gives oral liquid, and negative and positive controls is irritated stomach with distilled water, continuous 30 days.After the off-test, all animal fasting 48 hours are not restricted water supply, and all animal per os except that negative control group are irritated stomach dehydrated alcohol (1ml/ only).Put to death animal after 1 hour, dissect and get stomach, 20 minutes tailing edge greater gastric curvatures of 5% formaldehyde fixed are cut off, and clean gastric content, with the hyperemia of the every Mus stomach of vernier caliper measurement, hemorrhage and diffuse hemorrhage area.Experimental result Spss software statistics.
3.2 experimental result
Sample is to the influence of animal ulcer index
*Compare with positive controls (through variance analysis)
Credit is analysed by statistics, and negative control group is compared with positive controls, and the gastric mucosa injury area is significantly less than positive controls, and significant difference is arranged, and the modelling success is described; The gastric mucosa injury face of each dosage group of oral liquid obviously reduces with long-pending comparing with positive controls all, and significant difference is all arranged.
3.3 experiment conclusion: oral liquid has protective effect to gastric mucosa injury due to the rat ethanol.
Oral liquid of the present invention to human clinical's functional evaluation that 33 routine chronic gastritis shallow patients take January, confirms that it has the effect of protection gastric mucosa to the chronic superficial gastritis patient through Nanjing Medical University's nutrition and Food Science technical research institute, attached first hospital of Nanjing Medical University.Concrete test method and result are as follows:
1, materials and methods
Selection meets patient's 66 examples of chronic superficial gastritis Western medicine diagnose standard and differential diagnosis in tcm, age 16-65 year (average 43.3 years old), average course of disease 7.11 years, complication persons such as no severe cardiac, liver, kidney, be divided into test-meal group and matched group at random, the test-meal group is taken oral liquid, every day the 50ml/ bottle; It is peaceful that matched group is taken Veytalo, took continuously 30 days.Adopt control design between own control and two groups in each group, observe the variation of effect index (clinical symptoms and sign, gastroscope check, blood fat, fasting glucose) and safety indexes (routine blood test, hepatic and renal function).
2, result of the test
Main clinic symptoms is improved situation before and after the test-meal
Show and take that test-meal group and the every clinical symptoms of matched group all have improvement after the oral liquid, difference that relatively there are no significant between two groups of every clinical symptoms (P〉0.05)
Effect relatively after the test-meal
The result shows that test-meal group improvement rate is 63.64%, and matched group improvement rate is not have significant difference (P〉0.05) between 60.61%, two group.
By the detection to every safety indexes such as liver, renal function (total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, blood urea nitrogen, flesh liver), routine blood test (erythrocyte, leukocyte, hemoglobin), blood fat (cholesterol, triglyceride), fasting glucose before and after test-meal group and the matched group test-meal, the result shows that every safety indexes is all in normal range in addition.
3, conclusion (of pressure testing)
33 routine chronic gastritis patients took oral liquid after one month, and main clinic symptoms and sign make moderate progress; Do not see untoward reaction in the test-meal.According to " the health food function assessment assessment process and the method for inspection " criterion, it has the effect of protection gastric mucosa to the chronic gastritis patient.
Oral liquid of the present invention is not seen toxic and side effects and teratogenesis, carcinogenic, genotoxicity through acute toxicity test, micronucleus test, sperm malformation test, Salmonella reversion test and 30 days feeding trials.
The specific embodiment:
Following embodiment can be for reference in order to further specify the present invention, but do not limit the scope of the invention thus.
Embodiment 1
Use following weight Chinese crude drug raw material among the every 1000ml of oral liquid of the present invention, the adding pharmaceutical adjunct is processed into after processes such as extraction, precipitate with ethanol:
Pericarpium Citri Reticulatae 160g Radix Rhodiolae 120g Radix Angelicae Sinensis 85g
Semen Hoveniae (Fructus Hoveniae) 120g Rhizoma Zingiberis 105g Radix Bupleuri 150g
Radix Puerariae 85g Radix Salviae Miltiorrhizae 105g Herba Centellae 120g
Preparation method:
Take by weighing Radix Puerariae, Semen Hoveniae (Fructus Hoveniae), Radix Rhodiolae, Pericarpium Citri Reticulatae, Rhizoma Zingiberis, Radix Bupleuri, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis and the Herba Centellae that is ground into coarse powder by proportioning, added water infiltration 2 hours, adding water to 10 times, 8 times amounts respectively decocts 2 times, each two hours, filter, merging filtrate is evaporated to 1/2 of medical material weight, forms the Chinese medicine concentrated solution; 95% alcoholic solution that adds 3 times of amounts (volume ratio) stirs half an hour, precipitate with ethanol 24 hours; Filter, reclaim ethanol to there not being the alcohol flavor, cooling back adding distil water standardize solution forms Chinese medicine extraction liquid to 1.5 times of the medical material total amount; Add sucrose 50g, high fructose syrup 50g and citric acid 1g, mix homogeneously by proportioning; Be warming up to 90-100 ℃, heat sterilization is incubated half an hour, is cooled to 30 ℃, adds Herba Menthae essence 1g and sodium benzoate 1.8g, and fully mixing is added distilled water to full dose; Behind plate-and-frame filtration, be filled into bottle, the 50ml/ bottle.
Oral liquid is that light coffee color, density are that 1.082g/ml, pH value are 4.5 liquid.
Instructions of taking: 1 bottle of every day.
Embodiment 2
Use following weight Chinese crude drug raw material among the every 1000ml of oral liquid of the present invention, the adding pharmaceutical adjunct is processed into after processes such as extraction, precipitate with ethanol:
Pericarpium Citri Reticulatae 170g Radix Rhodiolae 130g Radix Angelicae Sinensis 100g
Semen Hoveniae (Fructus Hoveniae) 130g Rhizoma Zingiberis 120g Radix Bupleuri 150g
Radix Puerariae 100g Radix Salviae Miltiorrhizae 120g Herba Centellae 100g
Preparation method:
Take by weighing Radix Puerariae, Semen Hoveniae (Fructus Hoveniae), Radix Rhodiolae, Pericarpium Citri Reticulatae, Rhizoma Zingiberis, Radix Bupleuri, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis and the Herba Centellae that is ground into coarse powder by proportioning, added water infiltration 2 hours, adding water to 10 times, 8 times amounts respectively decocts 2 times, each two hours, filter, merging filtrate is evaporated to 1/2 of medical material weight, forms the Chinese medicine concentrated solution; 95% alcoholic solution that adds 3 times of amounts (volume ratio) stirs half an hour, precipitate with ethanol 24 hours; Filter, reclaim ethanol to there not being the alcohol flavor, cooling back adding distil water standardize solution forms Chinese medicine extraction liquid to 1.5 times of the medical material total amount; Add protein sugar 2g, high fructose syrup 50g and citric acid 1g, mix homogeneously by proportioning; Be warming up to 90-100 ℃, heat sterilization is incubated half an hour, is cooled to 30 ℃, adds coffee aroma 1.5g and sodium benzoate 1.8g, and fully mixing is added distilled water to full dose; Behind plate-and-frame filtration, be filled into bottle, the 50ml/ bottle.
Oral liquid is that light coffee color, density are that 1.085g/ml, pH value are 4.6 liquid.
Instructions of taking: 1 bottle of every day.
The present invention adopts the beneficial effect of above technical scheme to be:
1, fills a prescription rationally, has no side effect, be suitable for long-term taking.
The present invention utilizes prescription advantage, the good Chinese herbal medicines of selection security of motherland's Chinese Traditional Medicine, uses modernized Chinese medicine processing technology to be prepared from. Both avoided the toxic and side effect that produces behind the Western medicine long-term taking, overcome again Chinese medicine because of the uncomfortable needs that are difficult to satisfy health care of some component dosage, and reached the purpose of liver-protecting and stomach-nourishing from the angle of prevention and health care, and be suitable for long-term taking.
2, the double effects that has liver-protecting and stomach-nourishing.
The crowd's liver of drinking for a long time is subject to the ethanol infringement and produces fatty liver, alcoholic cirrhosis; gastric mucosa is also because stimulating the impaired symptoms such as a series of stomach wrists, pain, belch, pantothenic acid that produce simultaneously; the present invention considers again the protection to gastric mucosa in beneficial liver, can reach double effects.
3, be easy to after taking absorb, effect rapidly, can comparatively fast remove malaise symptoms.
Formulation of the present invention is oral liquid, and is bigger than the decentralization of corresponding solid pharmaceutical preparation, contacts widely, is easy to absorption of human body, and effect can comparatively fast improve the symptoms such as produce because wine by the emperor himself is excessive drunk, dizzy, stomachache, poor appetite rapidly.
4, preparation stabilization, mouthfeel are better.
Have the character instability, easily be that Institute of Micro-biology pollutes and the characteristics such as mouthfeel difference for liquid preparation, the essence that adds suitable anticorrisive agent, sweetener and different taste in the oral liquid of the present invention, not only guaranteed the stability of preparation, simultaneously also improve taste, more met modern's mouthfeel demand.
Claims (7)
1. the compound oral liquid with liver-protecting and stomach-nourishing function is characterized in that using following weight raw material among the every 1000ml of described oral liquid, is processed into through extraction, precipitate with ethanol, adding pharmaceutical adjunct:
Pericarpium Citri Reticulatae 150-170g Radix Rhodiolae 110-130g Radix Angelicae Sinensis 80-100g
Semen Hoveniae (Fructus Hoveniae) 110-130g Rhizoma Zingiberis 100-120g Radix Bupleuri 150-170g
Radix Puerariae 80-100g Radix Salviae Miltiorrhizae 100-120g Herba Centellae 100-150g.
2. compound oral liquid according to claim 1 is characterized in that adding following pharmaceutical adjunct: sweeting agent 50-100g, antiseptic 0.2-2g, aromatic 0.5-2g, citric acid 0.5-1.5g, distilled water surplus;
Described sweeting agent is one or more the mixture that is selected from sucrose, high fructose syrup, protein sugar, crude sweet echinacoside, the saccharin sodium;
Described antiseptic is one or more the mixture that is selected from benzoic acid, sodium benzoate, sorbic acid, sodium sorbate, methyl hydroxybenzoate, ethyl hydroxybenzoate, the propylparaben;
Described aromatic is to be selected from a kind of in Herba Menthae essence, coffee aroma, osmanthus flower fragrance, strawberry essence, the flavoring pineapple essence.
3. compound oral liquid according to claim 1 and 2 is characterized in that this oral liquid is that light coffee color, density are that 1.05-1.15g/ml, pH value are the liquid of 4-6.
4. compound oral liquid according to claim 1 and 2 is characterized in that functional component and content are among the every 100ml of this oral liquid: total flavones 110-140mg; Puerarin 15-20mg; Rhodioside 25-30mg.
5. compound oral liquid according to claim 1 and 2 is characterized in that described oral liquid has the effect of protection chemical liver injury.
6. compound oral liquid according to claim 1 and 2 is characterized in that described oral liquid has the effect of protection gastric mucosa injury.
7. the preparation method of a compound oral liquid as claimed in claim 1 or 2 may further comprise the steps:
A. take by weighing Radix Puerariae, Semen Hoveniae (Fructus Hoveniae), Radix Rhodiolae, Pericarpium Citri Reticulatae, Rhizoma Zingiberis, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Radix Bupleuri, the Herba Centellae that is ground into coarse powder by proportioning, added water infiltration 2 hours, adding water to 10 times, 8 times amounts respectively decocts 2 times, each two hours, filter, merging filtrate is evaporated to 1/2 of medical material weight, forms the Chinese medicine concentrated solution;
B. in the Chinese medicine concentrated solution, add 95% alcoholic solution of 3 times of amounts of Chinese medicine concentrated solution volume, stir half an hour, precipitate with ethanol 24 hours; Filter, filtrate recycling ethanol is not to there being the alcohol flavor, and cooling back adding distil water standardize solution forms Chinese medicine extraction liquid to 1.5 times of the medical material total amount;
C. by proportioning, in Chinese medicine extraction liquid, add sweeting agent and citric acid, mix homogeneously;
D. be warming up to 90-100 ℃, heat sterilization is incubated half an hour, is cooled to 30 ℃, adds aromatic and antiseptic, and fully mixing is added distilled water to full dose;
E. behind plate-and-frame filtration, be filled into bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100310126A CN101143203B (en) | 2006-09-11 | 2006-09-11 | Compound oral liquid with liver-protecting and stomach-nourishing function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100310126A CN101143203B (en) | 2006-09-11 | 2006-09-11 | Compound oral liquid with liver-protecting and stomach-nourishing function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101143203A CN101143203A (en) | 2008-03-19 |
| CN101143203B true CN101143203B (en) | 2010-12-08 |
Family
ID=39206057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100310126A Active CN101143203B (en) | 2006-09-11 | 2006-09-11 | Compound oral liquid with liver-protecting and stomach-nourishing function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101143203B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109793766A (en) * | 2019-03-29 | 2019-05-24 | 王硕 | The preparation method and applications of Gotu Kola oral solution |
| CN112076251A (en) * | 2019-06-13 | 2020-12-15 | 陈奕帆 | Health tea for treating stomach diseases |
| CN112220866A (en) * | 2020-10-30 | 2021-01-15 | 重庆希尔安药业有限公司 | Superior-taste heat-clearing composition oral liquid |
-
2006
- 2006-09-11 CN CN2006100310126A patent/CN101143203B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 邓家刚，周小雷.中药抗肝损伤作用实验研究进展.广西中医药第29卷 第1期.2006,第29卷(第1期),1-3. |
| 邓家刚,周小雷.中药抗肝损伤作用实验研究进展.广西中医药第29卷 第1期.2006,第29卷(第1期),1-3. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101143203A (en) | 2008-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645385B1 (en) | Composition for anti-obesity | |
| CN104068284B (en) | For mixed feed treating gosling plague and preparation method thereof | |
| CN101095751B (en) | Medicinal composition having functions of removing chloasma and improving nutritional anemia and method for preparing the same | |
| CN103417837B (en) | Medlar health preserving cream of a kind of medicine-food two-purpose and preparation method thereof | |
| CN105686006B (en) | One seed oyster composite function food and preparation method thereof | |
| CN104398986A (en) | Tranquilization and brain tonifying epimedium herb oral liquid and preparation method thereof | |
| WO2008061447A1 (en) | A medicine for treating eczema and process of ointment thereof | |
| CN101143203B (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN103432192B (en) | A kind of compositions with antiobesity action | |
| KR100786122B1 (en) | Composition effective for prevention and treatment of obesity which contains crude drug extract | |
| KR100678519B1 (en) | A composition comprising the extract of Semisulospira libertine Sulfur Fed Duck Ulmus devidiana Pine Pollen Powder Acer tegmentosum Maxim. Bamboo Salt Artemisia capillaries Platycodon Grandiflorum Rhynchosiavolubilis for the prevention and treatment of fatty liver | |
| KR101160088B1 (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| KR101689259B1 (en) | Composition having effects of preventing or recovering fatigue or stress | |
| CN106692742A (en) | Traditional Chinese compound medicine for regulating blood sugar and preparation method of traditional Chinese compound medicine | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN101745042B (en) | Composition with effects of relieving alcoholism and protecting liver and preparation method thereof | |
| CN101474346A (en) | Longstamen onion bulb extract as well as preparation method and application thereof | |
| KR20100094223A (en) | The drinking water composition for dissolution of hangover | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN103719661B (en) | Blood-enriching oral liquid health products | |
| KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
| CN104585469A (en) | Chewing gum having protective effect on alcoholic liver injury and preparation method of chewing gum | |
| CN105597083B (en) | A kind of pair of liver kidney has health food of auxiliary protection function and preparation method thereof | |
| CN114982972B (en) | Method for preparing qi-yin-deficiency health care capsule food by extracting high-quality protein from blood meat animals and Chinese herbal medicines | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound oral liquid with liver-protecting and stomach-nourishing function Effective date of registration: 20130301 Granted publication date: 20101208 Pledgee: Bank of China Limited by Share Ltd. Shanghai Putuo branch Pledgor: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. Registration number: 2013310000009 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150506 Granted publication date: 20101208 Pledgee: Bank of China Limited by Share Ltd. Shanghai Putuo branch Pledgor: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. Registration number: 2013310000009 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound oral liquid with liver-protecting and stomach-nourishing function Effective date of registration: 20150512 Granted publication date: 20101208 Pledgee: Bank of China Limited by Share Ltd. Shanghai Putuo branch Pledgor: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. Registration number: 2015310000017 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180227 Granted publication date: 20101208 Pledgee: Bank of China Limited by Share Ltd. Shanghai Putuo branch Pledgor: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. Registration number: 2015310000017 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190510 Address after: Room 304-12, 665 Zhangjiang Road, Shanghai Free Trade Pilot Area, 201210 Patentee after: Shanghai Huilun Pharmaceutical Technology Co.,Ltd. Address before: Room 650-10, Building No. 2, 351 Guoshoujing Road, Zhangjiang High-tech Park, Shanghai, 201203 Patentee before: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190815 Address after: Room 650-10, Building No. 2, 351 Guoshoujing Road, Shanghai Free Trade Pilot Area, 201203 Patentee after: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Room 304-12, 665 Zhangjiang Road, Shanghai Free Trade Pilot Area, 201210 Patentee before: Shanghai Huilun Pharmaceutical Technology Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Room 650-10, Building No. 2, 351 Guoshoujing Road, Shanghai Free Trade Pilot Area, 201203 Patentee after: Shanghai Hui Bio Technology Co.,Ltd. Address before: Room 650-10, Building No. 2, 351 Guoshoujing Road, Shanghai Free Trade Pilot Area, 201203 Patentee before: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 200241 floor 10, building 5, No. 525, Yuanjiang Road, Minhang District, Shanghai Patentee after: Shanghai Huilun Pharmaceutical Co.,Ltd. Address before: Room 650-10, building 2, 351 GuoShouJing Road, Shanghai pilot Free Trade Zone, 201203 Patentee before: Shanghai Hui Bio Technology Co.,Ltd. |